Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients

Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increas...

Source: Journal of Experimental and Clinical Cancer Research - November 14, 2023 Category: Cancer & Oncology Authors: Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Ru Tags: Research Source Type: research